These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25714783)

  • 1. Cervical cancer epidemiology in foreign women in Northern Italy: role of human papillomavirus prevalence in country of origin.
    Di Felice E; Caroli S; Paterlini L; Campari C; Prandi S; Giorgi Rossi P
    Eur J Cancer Prev; 2015 May; 24(3):223-30. PubMed ID: 25714783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology.
    Stoler MH; Wright TC; Parvu V; Yanson K; Eckert K; Kodsi S; Cooper C
    Am J Clin Pathol; 2019 Mar; 151(4):433-442. PubMed ID: 30649177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants.
    Wang SS; Zuna RE; Wentzensen N; Dunn ST; Sherman ME; Gold MA; Schiffman M; Wacholder S; Allen RA; Block I; Downing K; Jeronimo J; Carreon JD; Safaeian M; Brown D; Walker JL
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):113-20. PubMed ID: 19124488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple human papillomavirus infection with or without type 16 and risk of cervical intraepithelial neoplasia among women with cervical cytological abnormalities.
    Spinillo A; Gardella B; Roccio M; Alberizzi P; Cesari S; Patrizia M; Silini E
    Cancer Causes Control; 2014 Dec; 25(12):1669-76. PubMed ID: 25296710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California.
    Hammer A; Demarco M; Campos N; Befano B; Gravitt PE; Cheung L; Lorey TS; Poitras N; Kinney W; Wentzensen N; Castle PE; Schiffman M
    Int J Cancer; 2020 Sep; 147(6):1612-1620. PubMed ID: 32141607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
    Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
    BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triaging women with human papillomavirus infection and normal cytology or low-grade dyskaryosis: evidence from 10-year follow up of the ARTISTIC trial cohort.
    Gilham C; Sargent A; Peto J
    BJOG; 2020 Jan; 127(1):58-68. PubMed ID: 31541495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy.
    Carozzi FM; Tornesello ML; Burroni E; Loquercio G; Carillo G; Angeloni C; Scalisi A; Macis R; Chini F; Buonaguro FM; Giorgi Rossi P;
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2389-400. PubMed ID: 20826836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.
    Uijterwaal MH; Polman NJ; Van Kemenade FJ; Van Den Haselkamp S; Witte BI; Rijkaart D; Berkhof J; Snijders PJ; Meijer CJ
    Cancer Prev Res (Phila); 2015 Jun; 8(6):502-8. PubMed ID: 25776933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Human Papilloma Virus (HPV), cervical cancer incidence and screening uptake: differences among Northern, Central and Southern Italy].
    Giorgi Rossi P; Chini F; Borgia P; Guasticchi G; Carozzi FM; Confortini M; Angeloni C; Buzzoni C; Buonaguro FM;
    Epidemiol Prev; 2012; 36(2):108-19. PubMed ID: 22706361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
    Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
    JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus type distribution in cervical intraepithelial neoplasia grade 2/3 and cervical cancer in Portugal: a CLEOPATRE II Study.
    Pista A; de Oliveira CF; Lopes C; Cunha MJ;
    Int J Gynecol Cancer; 2013 Mar; 23(3):500-6. PubMed ID: 23392401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population-based study on the risk of cervical cancer and cervical intraepithelial neoplasia among grand multiparous women in Finland.
    Hinkula M; Pukkala E; Kyyrönen P; Laukkanen P; Koskela P; Paavonen J; Lehtinen M; Kauppila A
    Br J Cancer; 2004 Mar; 90(5):1025-9. PubMed ID: 14997202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
    Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervical cancer screening in immigrant women in Italy: a survey on participation, cytology and histology results.
    Campari C; Fedato C; Iossa A; Petrelli A; Zorzi M; Anghinoni E; Bietta C; Brachini A; Brezzi S; Cogo C; Giordano L; Giorgi D; Palazzi M; Petrella M; Schivardi MR; Visioli CB; Giorgi Rossi P;
    Eur J Cancer Prev; 2016 Jul; 25(4):321-8. PubMed ID: 26207563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.
    Khan MJ; Castle PE; Lorincz AT; Wacholder S; Sherman M; Scott DR; Rush BB; Glass AG; Schiffman M
    J Natl Cancer Inst; 2005 Jul; 97(14):1072-9. PubMed ID: 16030305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results.
    Stoler MH; Wright TC; Parvu V; Vaughan L; Yanson K; Eckert K; Karchmer T; Kodsi S; Cooper CK
    Gynecol Oncol; 2018 Jun; 149(3):498-505. PubMed ID: 29681462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.